A Phase 3 interventional study of Docetaxel and 5-fluorouracil in Breast Cancer, sponsored by Sanofi. Completed at 20 sites in 20 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-02-16.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.
Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 18th largest by enrollment of the 248 interventional ones that give a count, is one of 5 that started in 1997, is one of 51 in phase 3, and was the 158th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai JMT-Bio Inc. · Sites in China
Ages 18+
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 178 · Phase 3 55 · Phase 4 5
First in 1993; this study’s year is marked. 5 started in 1997.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,491 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 248 interventional studies. Of the 207 that completed or were terminated, 58 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 264 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
40 studies in Breast Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 39 finished, 14 (36%) have results posted.
Among the 40 studies in Breast Neoplasms by Sanofi, this one is the 4th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 1997, is one of 11 in phase 3, and was the 20th registered.
Sanofi’s Breast Neoplasms studies by the year they started, since 1994.
3 of the studies testing docetaxel in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747338Phase 3Shanghai JMT-Bio Inc.A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | 2026-12-16 |
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 264 studies testing docetaxel in Breast Neoplasms, from their registry updates:
Among Sanofi’s 40 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable breast cancer patients with positive axillary lymph nodes.
In addition to the 5-year analysis conducted in September 2003, two other analyses were planned when 590 and 700 Disease Free Survival events occurred. However, due to the lower than predicted DFS event rate, and in agreement with FDA and EMA, a time-based final analysis at 10 years was considered more appropriate than an event-based (700 Disease Free Survival events) analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
docetaxel (75 mg/m\^2) in combination with doxorubicin (50 mg/m\^2) and cyclophosphamide (500 mg/m\^2) on day 1 every 3 weeks for 6 cycles of treatment
Drug: Docetaxel · Drug: Doxorubicin · Drug: Cyclophosphamide
5-fluorouracil (500 mg/m\^2) in combination with doxorubicin (50 mg/m\^2) and cyclophosphamide (500 mg/m\^2) on day 1 every 3 weeks for 6 cycles of treatment
Drug: 5-fluorouracil · Drug: Doxorubicin · Drug: Cyclophosphamide
intravenous
Also known as: Taxotere®
intravenous
Also known as: 5-FU
intravenous
intravenous
Number of Participants With Disease-Free Survival Events
Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.
Time frame: up to 10 year follow-up
Number of Participants With Overall Survival Events
Overall Survival - time from the date of randomization up to the date of death of any cause.
Time frame: up to 10 year follow-up
Number of Participants With Second Primary Malignancies (Toxicity)
Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.
Time frame: up to 10 year follow-up
Between June 1997 and June 1999, 1491 women from 20 countries were enrolled in the study. The last patient last visit occurred in January 2010.
| Milestone | TAC (Docetaxel) | FAC (5-fluorouracil) |
|---|---|---|
| Started | 745 | 746 |
| Completed | 679 | 711 |
| Not completed | 66 | 35 |
| Withdrew: Adverse event | 45 | 8 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Consent withdrawn | 17 | 17 |
| Withdrew: Breast cancer relapse | 1 | 4 |
| Withdrew: Violation of inclusion criteria | 1 | 3 |
Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.
| Participants | TAC (Docetaxel) | FAC (5-fluorouracil) |
|---|---|---|
| Number of Participants With Disease-Free Survival Events | 287 (0.579 to 0.650) | 333 (0.513 to 0.586) |
Overall Survival - time from the date of randomization up to the date of death of any cause.
| Participants | TAC (Docetaxel) | FAC (5-fluorouracil) |
|---|---|---|
| Number of Participants With Overall Survival Events | 188 (0.724 to 0.786) | 241 (0.651 to 0.719) |
Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.
| Participants | TAC (Docetaxel) | FAC (5-fluorouracil) |
|---|---|---|
| Number of Participants With Second Primary Malignancies (Toxicity) | 67 | 66 |
Collected over from date of randomization until the completion of the 10-year follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAC (Docetaxel) | — | 267/744 (35.9%) | 744/744 (100%) |
| FAC (5-fluorouracil) | — | 67/736 (9.1%) | 734/736 (99.7%) |
| Event | TAC (Docetaxel) | FAC (5-fluorouracil) |
|---|---|---|
| Fever in absence of infectionGeneral disorders | 187/744 | 24/736 |
| VomitingGastrointestinal disorders | 11/744 | 6/736 |
| NauseaGastrointestinal disorders | 8/744 | 3/736 |
| PharyngitisInfections and infestations | 7/744 | 1/736 |
| DiarrhoeaGastrointestinal disorders | 6/744 | 1/736 |
| PyrexiaGeneral disorders | 6/744 | 2/736 |
| StomatitisGastrointestinal disorders | 5/744 | 0/736 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/744 | 4/736 |
| Deep vein thrombosisVascular disorders | 1/744 | 4/736 |
| PneumoniaInfections and infestations | 4/744 | 2/736 |
| Event | TAC (Docetaxel) | FAC (5-fluorouracil) |
|---|---|---|
| Any skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 734/744 | 718/736 |
| AlopeciaSkin and subcutaneous tissue disorders | 728/744 | 715/736 |
| Any gastrointestinal disordersGastrointestinal disorders | 713/744 | 709/736 |
| Any general disorders and administration site conditionsGeneral disorders | 673/744 | 610/736 |
| NauseaGastrointestinal disorders | 599/744 | 647/736 |
| AstheniaGeneral disorders | 592/744 | 513/736 |
| StomatitisGastrointestinal disorders | 508/744 | 374/736 |
| VomitingGastrointestinal disorders | 327/744 | 436/736 |
| Any nervous system disordersNervous system disorders | 427/744 | 318/736 |
| PainGeneral disorders | 312/744 | 264/736 |
| Age, Categorical(Participants) | TAC (Docetaxel) | FAC (5-fluorouracil) | Total |
|---|---|---|---|
| Between 18 and 65 years | 697 | 705 | 1402 |
| >=65 years | 48 | 41 | 89 |
| Sex: Female, Male(Participants) | TAC (Docetaxel) | FAC (5-fluorouracil) | Total |
|---|---|---|---|
| Female | 745 | 746 | 1491 |
| Male | 0 | 0 | 0 |
| Number of Positive Nodes(participants) | TAC (Docetaxel) | FAC (5-fluorouracil) | Total |
|---|---|---|---|
| 1-3 Positive Nodes | 467 | 459 | 926 |
| 4 or More Positive Nodes | 278 | 287 | 565 |
The record gives a start of Jun 1997, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Docetaxel